title: 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.
abstract: The active and inactive stereoisomers of the serotonin (5-HT2) antagonist, MDL 11,939, were used to examine the relationship between the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on the dopaminergic system and its long-term effects on the serotonergic system. Only the R-(+) stereoisomer of MDL 11,939 both reversed the acute stimulation of striatal dopamine synthesis by MDMA and prevented the deficit in forebrain 5-HT concentrations measured one week later. This acute activation of striatal dopamine synthesis by MDMA is a compensatory response to the carrier-mediated efflux of transmitter as shown by its sensitivity to the dopamine uptake inhibitor, nomifensine. It is suggested that in the absence of this enhanced synthesis, the dopaminergic neuron cannot sustain the carrier-mediated dopamine release which is a prerequisite for the development of MDMA-induced neurotoxicity. This hypothesis is supported by the observation that the administration of the dopamine precursor, L-dopa, with MDMA reverses the protective effects of 5-HT2 receptor antagonists.
authors.affiliation: Merrell Dow Research Institute, Cincinnati, Ohio.
authors.forename: C J
authors.initials: CJ
authors.lastname: Schmidt
authors.forename: V L
authors.initials: VL
authors.lastname: Taylor
authors.forename: G M
authors.initials: GM
authors.lastname: Abbate
authors.forename: T R
authors.initials: TR
authors.lastname: Nieduzak
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D015104:3,4-Methylenedioxyamphetamine / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000096:biosynthesis* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D007980:Levodopa / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D009627:Nomifensine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D016713:Ritanserin; D012702:Serotonin Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D013237:Stereoisomerism; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D012702:Serotonin Antagonists; D015102:3,4-Dihydroxyphenylacetic Acid; C066169:alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol; D016713:Ritanserin; D009627:Nomifensine; D007980:Levodopa; D015104:3,4-Methylenedioxyamphetamine; D006220:Haloperidol; D004298:Dopamine; D006719:Homovanillic Acid